Status:
COMPLETED
Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy trea...
Eligibility Criteria
Inclusion
- Breast cancer with evidence of unresectable, locally recurrent or metastatic disease
- Candidate for treatment with docetaxel
Exclusion
- Prior chemotherapy in the advanced disease setting
- Inflammatory breast cancer
- HER2 positive disease
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00291577
Start Date
July 1 2006
End Date
February 1 2009
Last Update
December 23 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Brussels, Belgium, 1000
2
Pfizer Investigational Site
Milan, Italy, 20133
3
Pfizer Investigational Site
Stockholm, Sweden, 171 76